Zhong Guo Jing Ji Wang·2026-01-22 09:04Group 1 - The core point of the article is that Chengda Pharmaceutical (301201.SZ) is currently experiencing a decline in stock price, with a closing price of 39.67 yuan and a drop of 4.16%, indicating that the stock is in a state of breaking its initial public offering (IPO) price [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 20, 2022, with an initial public offering of 24,174,035 shares at a price of 72.69 yuan per share [1] - On its first day of trading, the stock reached a peak price of 188.00 yuan, which remains the highest point since its listing [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising amount exceeded the originally planned amount by 1,108.17 million yuan, with the initial target set at 513.28 million yuan for projects including "pharmaceutical intermediates, raw materials, and R&D center expansion" as well as "supplementing working capital" [1] - The total issuance costs for the IPO were 135.76 million yuan, with underwriting fees amounting to 117.93 million yuan [2] Group 3 - The actual controllers of Chengda Pharmaceutical are Ge Jianli, Lu Gang, and Lu Jin, with Lu Jin being a Chinese national who holds permanent residency in Canada [3] - On July 3, 2023, the company announced its 2022 annual equity distribution plan, which involves a cash distribution of 3.00 yuan for every 10 shares and a capital reserve increase of 6.00 shares for every 10 shares [3] - The record date for the equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [3]